Panel to MDs: Avoid Valproate in Fertile Women

BY MICHELE G. SULLIVAN

Mid-Atlantic Bureau

NEW ORLEANS — Valproate should not be prescribed as first-line therapy for any indication in women of childbearing age because it significantly increases the risk of major malformations in exposed infants, the American Epilepsy Society's pregnancy outcomes forum panel recommended.

Converging data from six studies presented at the annual meeting of the American Epilepsy Society and two recently published studies prompted the recommendation, said Kimford Meador, M.D., director of the epilepsy program at the University of Florida, Gainesville, and a member of the panel.

"This isn't class I evidence—we're never going to have that-but what is the chance that these different studies in different populations would all come to this same conclusion?" Dr. Meador asked. "In my opinion, this drug should not be used as first-line therapy for this population."

The studies presented linked valproate with up to a sevenfold increased relative risk of major malformation, compared with the general population; the rate of malformations was 10% for these infants and 1.6% in the general population.

Cardiac, neural tube, and multiple anomalies were among the malformations noted. None of the registries had high enough power to determine the risks for any particular malformation, however,

said Lewis Holmes, M.D., chief of the genetics and teratology unit at Massachusetts General Hospital, Boston, and the director of the North American Antiepileptic Drug Pregnancy Registry, which is managed by the hospital.

The registry was established in 1977; as of July 2004, it included 3,708 women. Sixteen infants with major malformations have been born to 149 valproate-exposed women (10.7% and a relative risk of 7.3).

In light of these findings, the panel agreed, physicians should offer safer medications for epilepsy, migraine, and mood disorders to fertile women. "There are lots of other equally effective medications for many of these women," said panelist Martha Morrell, M.D., of Stanford (Calif.) University.

For women with epilepsy, one such alternative is lamotrigine. "Several studies have indicated that the rate of major malformations associated with this drug is about 3%-similar to what we see in the general population," Dr. Morrell said.

The panel acknowledged that for some women, valproate's benefits outweigh the risks. "There may be patients for whom this is the only effective drug," said panelist Gregory Barkley, M.D., chair of the Epilepsy Foundation's professional advisory board. "These women should be counseled to avoid pregnancy," said Dr. Barkley, professor of neurology at Wayne State University, Detroit.

Valproate is the most frequently prescribed antiepileptic drug, with 12 million prescriptions written annually to women of childbearing years. Only about 20% of those prescriptions are for epilepsy-the rest are for migraine and mood disorders.

But many primary care providers and psychiatrists appear unaware of valproate's significant teratogenicity. Treatment guidelines for mood disorders, which recommend the use of valproate, don't include warnings of its effect on developing fetuses, Dr. Morrell said.

Even neurologists may not fully appreciate the problem, Dr. Holmes said. A patient referred to him said her neurologist told her that folic acid supplements would counteract valproate's increased risk of neural tube defects.

"There are no published data supporting that," he said. Anecdotal evidence indicates that the normal 1-mg dose of folate does not change the increased risk.

The recommendation to decrease valproate exposure makes "intuitive sense," said Lee Cohen, M.D., director of the perinatal and reproductive psychiatry clinic at Massachusetts General Hospital.

"It's an ugly drug for reproductive-aged women," he said. Numerous published and ongoing studies have documented behavioral abnormalities and developmental delay in children prenatally exposed to the drug; it also increases the risk of polycystic ovary disease in women who take it.

Panel members want to encourage U.S. and Canadian physicians to have pregnant patients who are taking any antiepileptic drug join the Antiepileptic Drug Pregnancy Registry. More information is available by calling 888-233-2334 or by going to www. aed pregnancy registry. org.

References: 1, Scharf MB, Roh T, Vogel CW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychotry. 1994;55:192-199. 2. Roh T, Roehrs T, Vogel C, Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo. Sieps. 1995;182:462-51. 3. Elie R, Rüther E, Farr I, Emilien G, Salinas E, for the Zaleplon Clinical Study Group. Seep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonberorduzepine rypropic. J Clin Psychotry 1999;65:363-464. A MRIBEN Prescripting Information, non-bi-syntheblob Lone. So, Office of Applied Studies. Dury abuse Visions. Drug Abuse Visions Provided Studies (1) and the Studies of Studies of Studies Visions (1) and the Studies of Studies Visions (1) and the Studies of Studies Visions (1) and the Studies (1) and the Studies Visions (1) and the Studies Visions (1) and



BRIEF SUMMARY

INDICATIONS AND USAGE

CONTRAINDICATIONS

CONTRANDICATIONS

one sleep disturbances may be the presenting manifestation of a physical rule of possibility of the present of the present

interiorie, the recommended Ambien dosage is 5 mg in such patients (see Desage and Ambientstadion) to decrease the possibility of side effects. These patients should be clearly immitted.

Bee in patients with concentrate filenses: Clinical experience with Ambien in Desage and Ambien in patients with diseases or conditions that could affect metabour and the patients of the patients with patients with mild-conderta sleep apnea when treated with Ambien (10 mg) when compared to placebo, However, precautions should be considered in the patients of the patients with pre-existing respiratory insufficiency, most of which involved patients with pre-existing respiratory impariment, have been received. Data in end-stage and failure patients repeatedly treated with Ambien did not demonstrate the patients with patients of the patie

Laboratory tests: There are no specific laboratory tests recommended.

didive effect on psychomotor performance between alcohol and colpi-se demonstrated, gle-does interaction study with zolpidem 10 mg and fluosetine 20 mg. set bennester and volunteers did not demonstrate any clinically signifi-ism and fluosetine at least-y-date concentrations were evaluation in healthy set and the set of set of

compared robes had cross-seats with Destrobuspines, upleates, bardhurdanes, Compared robes had cross-seats with the compared to the drug screens. Carbinogenesis, ratiogenesis, regardens of lending Carbinogenesis, Tallodiem was administered to risk and mice for 2 years at dictary dosages of 4.18, and 80 mg/dgg/dsr, Irmice, these doses are 26 to 52 times or 2 to 35 times the maximum 10-rap human dose on a mg/kg or ngim' basis, respectively, in the street doses are 4.5 to 875 times or 6 to 115 times the maximum 10-rap human dose on a mg/kg or ngim' basis, respectively, in the street doses on a mg/kg or ngim' basis, respectively, in the street doses on a mg/kg or ngim' basis, respectively, in the street doses on a mg/kg or ngim' basis, respectively, in the street doses on a mg/kg or ngim' basis, respectively, in the waste of 10 times was one of 10 times of 10 times on a mg/kg or ngim' basis, respectively, in developing the seen in 4100 ratio of 10 times the maximum through the street of 10 times was one of 10 times of 10 times

able fetuses. This drug should be used during pregnancy only if clearly needed.

This drug should be used during pregnancy only if dearly needed. Montreatogenic effects: Studies to sease the effects on children whose mothers took zolgidem during pregnancy have not been conducted. However, children born of mothers taking sedative/hyproidic drugs may be a some risk for with drawal symptoms from the drug during the postnatal period. In addition, necental flacacidly has been reported in inlatition born of mothers who received sedatively hyproide drugs during pregnancy. Labor and delivery. Ambrian has no established use in labor and delivery. Nursing mothers: Studies in latetating mothers indicate that between Q004 and Q019s of the total administered does se excreted into milk, but the effect of zolg-dem on the littent is unknown.

have not been established. Gentatric use: A total of 154 patients in U.S. controlled clinical trials and 897 patients in non-1.3, clinical trials who received zolpidem were 260 years of age, For a pool of U.S. patients receiving zolpidem at doses of 510 mg or placibo, there were three adverse events occurring at an incidence of last 83% for zolpi-dem and for which the zolpidem incidence was at least twice the placebo inci-dence ligit, they could be considered from gratadol.

Adverse Event	Zolpidem	Placebo
Dizziness	3%	0%
Drowsiness	5%	2%
Diarrhea	3%	1%

Controlled substance: Schedule V.

Abuse and dependence: Schedule V.

Abuse and schedule

sanofi~synthelabo